With the development of molecular biology, an increasing number of molecular markers have been illustrated to be of great significance for the individualized treatment and clinical prognosis of glioma, such as isocitrate dehydrogenase (IDH) mutation (5), chromosomal 1p/19q combined deletion state (6), and methylation of the promoter region of O6-methylguanine-DNA methyltransferase (MGMT) (7). Here, IDH1 is linked to central nervous system cancer.